|
Learn best business strategies
Balancing the supply and demand of influenza vaccines in Asia is a challenge for vaccine manufacturers and public health leaders. Predicting the demand during a pandemic as well as producing the vaccines at the fastest time possible is of highest concern in the industry. Learn from leading experts as they talk about the advanced technologies, developments and strategies in overcoming these challenges.
World Influenza Congress Asia is:
- Where Asian and global influenza vaccine buyers and sellers convene to talk about their latest developments and findings
- Where you can find out the flu market’s updates and trends that have impacts in your business in Asia
- Where the most relevant challenges in influenza from development to manufacturing will be discussed in detail
Your most important influenza vaccine platform
In light with the H1N1 incident, an increased focus has been given to influenza vaccines. Global and local pharmas race to produce the most cost efficient and effective flu vaccine. The demand for influenza vaccine has never been this high in the region. Pharmas and public health leaders are working together to ensure that supply will be able to meet the requirements in Asia.
Find out more from the brochure
|
|
Distinguished speakers at
World Influenza Congress Asia 2010
|
|
 BG Rhee, President, Green Cross, Korea
|
|
 Mark Simmerman, Director, Medical Affairs and Public Policy, Asia Pacific, Sanofi Pasteur
|
|
 Carlton Brown, Chief Executive Officer, Immune Targeting Systems (ITS), UK
|
 Andy Sheldon, President and Chief Executive Officer, Medicago, Canada |
 Nikolai Petrovsky, Chaiman, Vaxine, Australia |
|
 Tim Hirst, Executive Chairman, Gamma Vaccines, Australia
|
|
 Malik Peiris, Chair Professor of Microbiology at The University of Hong Kong, Virologist at the Queen Mary Hospital and the Scientific Director of the HKU-Pasteur Research Centre at Hong Kong
|
|
 Bram Palache, Global Scientific Communication and Public Affairs Director for Influenza Vaccines, Solvay Biologicals, Netherlands
|
|
 Filip Dubovsky, Vice President, Clinical Development, Medimmune, USA
|
|
